A vascular malformation is an abnormal cluster of blood vessels or lymph vessels that forms before birth and grows with you throughout life. Unlike vascular tumors (such as infantile hemangiomas), which involve rapidly dividing cells and often shrink on their own, vascular malformations are structural errors in the way vessels developed. They never regress spontaneously. With an estimated incidence of about 10 cases per 100,000 people per year, they are not rare, though many go undiagnosed for years because symptoms can be subtle early in life.
How Vascular Malformations Are Classified
The International Society for the Study of Vascular Anomalies (ISSVA) divides vascular malformations into three main groups based on how blood moves through them: fast-flow lesions, slow-flow lesions, and developmental anomalies of named vessels (meaning a specific, identifiable vessel like a major vein or artery formed incorrectly).
The fast-flow versus slow-flow distinction matters because it determines what symptoms you experience, what complications are likely, and which treatments work best. Slow-flow malformations involve capillaries, veins, lymph vessels, or combinations of these. Fast-flow malformations involve direct connections between arteries and veins, bypassing the normal capillary network that usually slows blood down.
Venous Malformations
Venous malformations are the most common type of congenital vascular malformation. They appear as soft, compressible masses under the skin, often with a bluish or purple tint when close to the surface. Although present at birth, they aren’t always visible right away. Many become noticeable later in childhood or even adulthood, growing gradually alongside the body rather than appearing suddenly.
The sluggish blood flow inside these malformed veins creates a tendency for clotting. Small clots called phleboliths can form within the malformation, causing episodes of pain and swelling. Over time, venous malformations can also lead to tissue overgrowth in the affected area or limb. They tend to enlarge during moments that increase pressure in the veins, such as straining, and may swell noticeably during puberty or pregnancy due to hormonal changes. Some venous malformations remain a mild cosmetic concern, while others cause disabling pain that requires treatment.
About 60% of venous malformation cases involve a mutation in a gene called TEK (also known as TIE2), and roughly 25% carry a mutation in PIK3CA, a gene involved in cell growth signaling. These are somatic mutations, meaning they occurred randomly during fetal development rather than being inherited from a parent.
Lymphatic Malformations
Lymphatic malformations are abnormal collections of lymph fluid in sac-like structures. A nationwide study found them to be the most frequently diagnosed subtype, with an annual incidence of about 5.8 per 100,000 people. They come in two forms: macrocystic (large, fluid-filled cysts, historically called cystic hygromas) and microcystic (tiny cysts that infiltrate surrounding tissue, once called lymphangiomas).
The distinction between the two shapes is clinically important. Macrocystic lesions tend to be well-defined and respond better to treatment because a needle can access the large cysts directly. Microcystic lesions weave through tissue in a way that makes them harder to treat and more likely to cause serious problems, including intense pain, impaired organ function, and in some cases airway obstruction when located in the head or neck. PIK3CA mutations have been identified in the tissue of about 94% of patients with lymphatic malformations, making it the most genetically consistent subtype.
Arteriovenous Malformations
Arteriovenous malformations (AVMs) are the least common subtype, occurring at roughly 0.24 per 100,000 people per year, but they carry the highest risk of serious complications. In a normal circulatory system, capillaries sit between arteries and veins, slowing blood flow and allowing oxygen exchange. An AVM bypasses this step entirely, creating a direct, high-pressure connection between arteries and veins.
This abnormal shortcut forces blood through the malformation at dangerously high speeds. The vessel walls experience intense mechanical stress, which over time triggers remodeling: vessels dilate, weaken, and become increasingly fragile. Brain AVMs carry an annual hemorrhage risk between 1% and 33%, depending on features like location and drainage patterns. A hemorrhage from a brain AVM has a 5% to 25% chance of being fatal within one year, and survivors face a 25% to 40% risk of permanent neurological damage. Patients whose AVMs sit deep in the brain, drain into deep veins, have associated aneurysms, or first presented with a bleed face the highest annual risk. Genetic studies have linked many AVMs to mutations in KRAS, MAP2K1, and BRAF.
Capillary Malformations
Capillary malformations are the flat, pink-to-red skin discolorations commonly known as port-wine stains. They occur at about 2.3 per 100,000 people per year. Unlike the other types, they are confined to tiny vessels near the skin’s surface and rarely cause pain or functional problems on their own. However, they can darken and thicken over time, and when they appear in certain locations (particularly the forehead or around the eye), they may be associated with underlying conditions that affect the brain or eye. Mutations in the GNAQ and GNA11 genes account for a large share of capillary malformations.
How Vascular Malformations Are Diagnosed
Diagnosis often begins with a physical exam when classic signs are present, such as a compressible blue mass or a visible port-wine stain. Imaging confirms the diagnosis and reveals how deep the malformation extends.
MRI is the preferred tool. It provides excellent soft-tissue contrast, can map the full extent of a lesion, and when combined with MR angiography, it can capture the flow dynamics of fast-flow malformations in real time. Combined conventional and contrast-enhanced MR angiography has a reported sensitivity of 83% and specificity of 95% for distinguishing venous malformations from other types. Ultrasound with Doppler is a useful first step because it can quickly differentiate fast-flow from slow-flow lesions at the bedside, but it has limited depth penetration and a narrow field of view, so it often can’t show the full picture on its own.
Conventional arteriography (catheter-based imaging of arteries) is no longer used as a first-line diagnostic tool because of its invasive nature, but it still offers the highest resolution of small vessels. It may be reserved for complex fast-flow lesions when MRI results are unclear or when detailed vascular mapping is needed before a procedure.
Blood Clotting Complications
Slow-flow malformations, particularly venous malformations, can cause a condition called localized intravascular coagulopathy (LIC). Sluggish, turbulent blood flow inside malformed vessels damages the vessel lining and promotes clotting. The body then uses up clotting factors trying to manage these internal clots, which can be detected through elevated D-dimer levels in the blood. In one study, over 40% of patients with venous malformations had significantly elevated D-dimer levels.
LIC is a common source of the chronic pain that many patients experience. In extensive malformations, it can progress to a more widespread clotting disorder that depletes platelets and fibrinogen throughout the body, raising the risk of serious bleeding. This is why blood work is an important part of monitoring for patients with large slow-flow malformations.
Treatment Options
Treatment depends on the type, size, location, and symptoms of the malformation. Many small, asymptomatic malformations require nothing more than monitoring. When treatment is needed, the options range from minimally invasive procedures to surgery, and the goal is often symptom control rather than complete cure.
Sclerotherapy
Sclerotherapy involves injecting a chemical agent directly into the malformation under ultrasound guidance. The agent irritates and scars the vessel walls, causing them to collapse and shrink. Common agents include polidocanol, ethanol, and OK-432 (a preparation derived from bacteria that works particularly well for macrocystic lymphatic malformations). For venous malformations, sclerotherapy provides meaningful symptom relief in over 86% of cases and is estimated to be successful in 75% to 90% of cases overall. Most patients need more than one session, and recurrence is possible, but it remains the first-line treatment for symptomatic slow-flow malformations.
Embolization
For fast-flow lesions like AVMs, embolization is the primary approach. A catheter is threaded into the blood vessels feeding the malformation, and materials are injected to block blood flow. Ethanol is considered the most effective embolic agent for AVMs because it permanently destroys the core of the malformation. Other materials like surgical glue, polyvinyl alcohol particles, and coils can provide temporary improvement but rarely achieve a lasting cure on their own.
Surgery
Surgical removal is an option when the malformation is small, well-defined, and in a location where complete removal is feasible. However, only about 20% of vascular malformations are considered candidates for complete surgical removal. Partial removal often leads to regrowth, and surgery on extensive or deep malformations carries significant risks. When surgery is performed, it is often preceded by embolization to reduce blood flow and make the operation safer.
Compression and Symptom Management
For venous malformations in the arms or legs, compression garments are a simple and effective way to reduce daily swelling and discomfort. Low-dose aspirin may also help by reducing the painful clotting episodes that occur within malformed veins. These measures don’t shrink the malformation, but they can meaningfully improve quality of life between or instead of procedures.
Living With a Vascular Malformation
Because vascular malformations are present from birth and persist for life, management is typically a long-term process rather than a single fix. Many patients undergo multiple treatments over years, with the aim of keeping symptoms under control as the malformation evolves. Hormonal changes during puberty and pregnancy can trigger growth or worsening of symptoms, so these are periods when closer monitoring is particularly valuable. Treatment is best managed by a multidisciplinary team at a center experienced with vascular anomalies, as the overlap between types, the genetic complexity, and the range of available interventions require coordinated expertise.